^
    Back
    Association details:
    Biomarker:TNFRSF8 expression
    Cancer:Peripheral T-cell Lymphoma
    Regimen:CHEP-BV (Adcetris (brentuximab vedotin) + cyclophosphamide + doxorubicin hydrochloride + etoposide IV + prednisone)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

    Published date:
    11/04/2021
    Excerpt:
    The interim (n=46) ORR and CR rates (after 3 CHEP-BV cycles, except 1 pt after 2) were 96% and 59% (27 CR, 17 PR), respectively. At completion of CHEP-BV (n=46), the ORR was 91% with 80% CR (37 CR, 5 PR, 4 PD)….In a cohort of pts with mostly non-ALCL CD30-expressing PTCL, CHEP-BV (+/- ASCT) followed by BV consolidation was tolerable and effective.
    DOI:
    10.1182/blood-2021-151105